In adults with moderate-to-severe OSA and obesity, tirzepatide reduced apnea–hypopnea events vs. placebo - KIVIRID

In adults with moderate-to-severe OSA and obesity, tirzepatide reduced apnea–hypopnea events vs. placebo

Authors: Lawrence J. Cheskin, Selvi Rajagopal

Published: 2024-09-30

DOI: 10.7326/annals-24-02174-jc

Source: Full article

Abstract

No abstract found.